| Identification | Back Directory | [Name]
YS121 | [CAS]
916482-17-2 | [Synonyms]
YS121
YS121 Exclusive
HVJBWTVMRIOTEL-UHFFFAOYSA-N | [Molecular Formula]
C20H26ClN3O2S | [MDL Number]
MFCD18382121 | [MOL File]
916482-17-2.mol | [Molecular Weight]
407.96 |
| Chemical Properties | Back Directory | [Boiling point ]
557.4±50.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | [form ]
solution in acetate. | [pka]
3.04±0.21(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Microsomal prostaglandin E2 synthase-1 (mPGES-1), with cyclooxygenase-2 (COX-2), synthesizes PGE2, which is directly involved in signaling during inflammation, fever, and pain. 5-Lipoxygenase (5-LO) initiates the synthesis of leukotrienes (LTs), which are pro-inflammatory mediators. YS-121 is a dual inhibitor of mPGES-1 (IC50 = 3.9 μM) and 5-LO (IC50 = 4.1 μM). It effectively inhibits PGE2 and LT synthesis in both cell free and intact cell assays. Moreover, YS-121 (1.5 mg/kg, intraperitoneal) reduced pleural levels of PGE2 and LTB4 while blocking exudate formation and leukocyte infiltration in carrageenan-induced rat pleurisy. YS-121 has minor effects on COX-1 and COX-2, inhibiting these enzymes 24.8% and 38%, respectively, at 10 μM. | [Uses]
YS121 is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1; IC50=3.4 μM) and 5-lipoxygenase (5-LOX; IC50=6.5 μM). YS121 dose- dependently reduces PGE2 production with EC50=12 μM in IL-1β-stimulated A549 cells[1]. | [Definition]
ChEBI: Octanoic acid, 2-[[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]- is a medium-chain fatty acid. | [References]
[1] koeberle a, zettl h, greiner c, et al. pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin e2 synthase-1 and 5-lipoxygenase[j]. journal of medicinal chemistry, 2008, 51(24): 8068-8076.
[2] mehrotra s, morimiya a, agarwal b, et al. microsomal prostaglandin e2 synthase‐1 in breast cancer: a potential target for therapy[j]. the journal of pathology, 2006, 208(3): 356-363.werz o, greiner c, koeberle a, et al. novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid[j]. journal of medicinal chemistry, 2008, 51(17): 5449-5453.koeberle a, rossi a, zettl h, et al. the molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2, 3-dimethylphenylamino) pyrimidin-2-ylthio) octanoic acid (ys121), a dual inhibitor of microsomal prostaglandin e2 synthase-1 and 5-lipoxygenase[j]. journal of pharmacology and experimental therapeutics, 2010, 332(3): 840-848. |
|
|